Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF(V600E) Mutated Papillary Thyroid Cancer: Two Case Reports

Background: A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing of these two agents to ach...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Paul S., Pudusseri, Anita, Lee, Stephanie L., Eton, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2017
Materias:
Case Studies, and Patients with Remarkable Features or Rare Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874808/
https://www.ncbi.nlm.nih.gov/pubmed/28805135
http://dx.doi.org/10.1089/thy.2017.0106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874808/
https://www.ncbi.nlm.nih.gov/pubmed/28805135
http://dx.doi.org/10.1089/thy.2017.0106

Ejemplares similares